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Abstract: For patients presenting with acute dyspnea, an incorrect diagnosis could increase 
the mortality risk. When used in the evaluation of patients with acute symptoms, brain 
natriuretic peptide and N-terminal pro-brain natriuretic peptide (BNP and NT-proBNP, 
respectively) testing is highly sensitive for the diagnosis or exclusion of acute or chronic 
decompensated heart failure (HF). It has been demonstrated that BNP and proBNP levels 
can facilitate diagnosis and guide HF therapy. Natriuretic peptide (NP) levels are strictly 
related with HF severity; they are particularly increased in more advanced New York Heart 
Association (NYHA) classes and in patients with poor outcome. Therefore elevated NP 
levels were found to correlate with the severity of left ventricular systolic dysfunction, right 
ventricular dysfunction and pressures, and left ventricular filling alterations. However, the 
optimal use of NP determination agrees with patient history, physical examination, and all 
other diagnostic tools. There are some clinical conditions (ie, obesity, renal insufficiency 
anemia) for which the NP measurement is not diagnostic. Algorithm building taking into 
consideration all clinical and echocardiographic parameters, as well as NP measurements, 
may lead to the earlier identification and better risk stratification of patients with chronic HF, 
independently from etiology.
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Introduction
Chronic heart failure (CHF) is a condition occurring with increased frequency and 
particularly in older patients 75 years old. Its prevalence is between 0.8% and 
2% in the general population.1 Patients may be classified as having heart failure 
(HF) when presenting for the first time (de novo) with acute heart failure (AHF) 
or in decompensated worsening CHF. In both groups the presence and extent of 
coronary artery disease (CAD) may determine the initial, in-hospital, and post-
discharge management. Low blood pressure, renal impairment, and/or signs and 
symptoms refractory to standard therapy characterize advanced HF. De novo HF 
represents the remainder of patients presenting with AHF and may be classified 
further by dividing them into those with pre-existing risk for HF (eg, hypertension, 
CAD) without evidence of prior left ventricular (LV) dysfunction or structural 
abnormalities, and those with pre-existing cardiac structural abnormalities (eg, 
reduced ejection fraction [EF]) (Figure 1).2 Early diagnosis and categorization 
is very important for an effective therapy optimization and prognosis improve-
ment. However, categorization is often difficult because of nonspecific symptoms 
and the lack of a gold standard protocol for correct diagnosis. After traditional 
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first-line examinations (ECG, thorax radiography and 
clinical examination) echocardiography is the technique 
recommended for patients affected by HF, because of its 
diagnostic and etiologic capability.
European Guidelines (2008) emphasized the role of natri-
uretic peptides (NP) as potential markers for HF.3 Therefore, 
NPs seem to be independent mortality predictors in patients 
with CHF. Although most studies showed that brain natri-
uretic peptide (BNP) is a marker with a higher sensivity and 
specificity; however the application of this analysis in clini-
cal practice is often limited by the absence of a universally 
accepted normal range. A single determination of BNP at any 
time during the progression of chronic HF is a clinically use-
ful tool for risk stratification.4 The hypothesis that repeated 
measurements could carry prognostic information beyond 
a single measure was confirmed in different settings. The 
importance of repeated determinations is in monitoring the 
progression of disease and in evaluating the clinical effects 
of medical therapy.5 In the near future, algorithm building 
will take into consideration clinical and echocardiographic 
parameters as well as NP measurements, and this may better 
ensure the correct diagnosis and categorization for patients 
with worsening prognosis.
Natriuretic peptides and heart 
failure diagnosis
BNP is a hormone that is secreted predominantly by the 
ventricles, and reaches very high plasma concentrations in 
subjects with congestive HF or AHF. BNP is synthesized 
in the heart as a reaction to cardiac wall distension and 
stretching, and neurohormonal activation. The cardiomyo-
cytes synthesize a pre-propetptide (preproBNP 134 amino 
acids) which is split into a signal peptide and a propetptide 
(proBNP 108 amino acids). During secretion from the car-
diomyocytes, proBNP is split at a ratio of 1:1 into the physi-
ologically active BNP (32 amino acids) which corresponds 
to the C-terminal fragment, and the biologically inactive N-
terminal fragment (NT proBNP, 76 amino acids).6 Secreted 
NP leads to natriuresis and vasodilation activation with a 
concomitant inhibition of the renin–angiotensin system and 
adrenergic activity.7 An increase in plasma BNP concentra-
tion results in improved myocardial relaxation and has an 
important regulatory role in response to acute increases in 
ventricular volume by opposing vasoconstriction, sodium 
retention, and the antidiuretic effects of activated renin–
angiotensin–aldosterone system. However, plasma NP lev-
els are elevated in patients with acute myocardial infarction 
Acute
HF
No
CAD Preserved EF
Chronic
HF
CAD† Reduced EF
Figure 1 Classification of acute and chronic heart failure on the basis of coronary diseases and systolic dysfunction presence.
Modified with permission from Gheorghiade M, Pang PS. Acute heart failure syndromes. J Am Coll Cardiol. 2009;53:557–573. Copyright © 2009 elsevier.2
Abbreviations: HF, heart failure; CAD, coronary artery disease; eF, ejection fraction.
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and LV dysfunction; this increase persists during late phases 
of cardiac remodeling.8 Elevated peptide levels are directly 
correlated with prognosis, NYHA score, intra-ventricular 
pressure, pulmonary pressure, and inversely proportional to 
cardiac output.9 Increased plasma BNP concentrations have 
also been observed in hypertrophic cardiomyopathy, diastolic 
dysfunction and LV hypertrophy. In these circumstances, 
BNP levels appear related to the myocardial mass index, 
interventricular and posterior wall thickness.10 Several stud-
ies have confirmed the effectiveness of determining plasma 
BNP concentrations in patients presenting with acute dys-
pnea. Initial research led by Dao et al studied 250 subjects 
that were admitted to the department of emergency medicine 
with acute dyspnea, they demonstrated that patients diag-
nosed with cardiac dyspnea had significantly elevated plasma 
BNP concentrations while patients with non cardiogenic 
dyspnea they were significantly lower. This is perhaps the 
differential key in patients who present with acute dyspnea 
as they showed that plasma BNP concentrations of less than 
80 pg/mL had a 98% predictive negative value.11 In a second, 
larger study, BNP levels were measured in 321 patients: the 
authors confirmed that patients with HF had higher BNP 
levels than patients with dyspnea due to respiratory dis-
eases.12 The first multicenter study, Breathing not Properly 
Study, enrolled 1586 emergency-department patients that 
presented with acute dyspnea and were all submitted to 
BNP measurement. The gold standard for congestive HF 
was adjudicated by two independent cardiologists (blind to 
the laboratory results), who reviewed all clinical data and 
standardized scores. BNP values directly correlated with the 
NYHA functional class: a linear correlation was seen among 
patients in NYHA I (197 pg/mL) compared to patients in 
NYHA IV (978 pg/mL).13 In the same way, Lainchbury et 
al showed that concentrations of proBNP were considerably 
higher among patients with acute HF compared with those 
who had a dyspnea due to other causes.14 Importantly, in this 
and in subsequent trials of patients with acute symptoms, 
the optimal proBNP concentration for diagnosis of acute HF 
was found to be considerably higher than those observed in 
studies of outpatient evaluation. In this study, investigators 
compared the proBNP assay (Roche Diagnostics, India-
napolis, IN) with the Biosite BNP assay (San Diego, CA, 
USA) and demonstrated identical areas under the receiver 
operating characteristic (ROC) curve (0.89 for both), dem-
onstrating significant comparability of the two assays for the 
evaluation of the patient with acute symptoms.14 Although 
the population sample was different some common data 
emerged and the diagnosis of HF was confirmed by clini-
cal history. Several parameters like high venous pressure 
recruitment, increase of LV dimension, and interstitial edema 
detected using chest radiogram were evaluated. None of 
these procedures showed a similar diagnostic accuracy as 
plasma BNP analysis. BNP is not only a good marker for 
the diagnosis of HF but is also an excellent indicator of the 
severity of CHF as BNP values increase linearly in relation 
to the stage.3
Natriuretic peptide and outcome
In CHF patients NP measurement appears very important 
for risk stratification as high levels are associated with 
recurrent hospitalization and risk of sudden death.15 Studies 
using natriuretic peptides have suggested that predischarge 
BNP measurement appears a strong predictor for identify-
ing subsequent death or hospital admission at 6 months.16,17 
In patients with coronary disease and preserved ventricular 
function, BNP provides strong and incremental prognostic 
information to traditional risk factors.18 Although “hard 
targets” for proBNP values are not entirely defined, morbid-
ity and mortality in CHF appear to increase markedly with 
a proBNP concentration 500 pg/mL. The best evidence of 
the prognostic value of BNP in CHF comes from statistically 
robust controlled clinical trials that include a large number 
of clinically well-characterized patients from different sites. 
The first data on proBNP from such a trial came from the 
Australia–New Zealand Heart Failure Group.19 In approxi-
mately 300 patients with well-characterized chronic HF of 
ischemic etiology (LV ejection fraction [LVEF]  0.45) ran-
domized to receive carvedilol or placebo, levels of proBNP 
above the median were associated with increased risks for 
new decompensated HF events (relative risk [RR], 4.7; 95% 
confidence interval [CI], 2.2–10.3) and all-cause mortality 
(RR, 4.7; 95% CI, 2.0–10.9) during 18 months of follow-up, 
independently of age, NYHA functional class, LVEF, previ-
ous myocardial infarction, or previous HF admission. The 
most important Valsartan Heart Failure (Val-HeFT) trial, 
5010 patients (85% with blood samples collected at study 
entry) with mild-to-moderate chronic HF receiving recom-
mended medical therapy, were randomized to an angiotensin 
II type 1 receptor blocker or placebo.20 An increment of 500 
ng/L above the baseline concentration of proBNP carried an 
increased adjusted risk of 3.8% for mortality and 3.0% for 
hospitalization for HF. On multivariate analysis, proBNP 
ranked as the first prognostic factor in these patients – inde-
pendent of and more powerful than traditional risk factors, 
such as NYHA class, age, LV dilation, or renal dysfunction.21 
A single determination of proBNP at any time during the 
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progression of chronic HF provides a clinically useful tool 
for risk stratification. The Val-HeFT study showed NP to be 
prognostically superior to several other recognized neuro-
hormonal markers of risk in HF, including norepinephrine, 
renin activity, aldosterone, and endothelin. In a head-to-head 
comparison of BNP and proBNP including Val-HeFT study 
participants, baseline BNP and proBNP were powerfully and 
similarly related to both mortality and risk of admission with 
decompensated HF independent of, and more strongly than, 
any of a range of pertinent predictive demographic, clinical, 
and echocardiographic variables.21 As with acute HF, the 
hypothesis that repeated measurements could lead to more 
precise prognostic information respect to a single measure-
ment has been confirmed in different settings.9,10 The value 
of repeated determinations of NP levels appears to be very 
important for monitoring the progression of heart disease and 
may help in evaluating the clinical effects of medical therapy. 
For instance, changes in NP levels during hospitalization 
were independent predictors of hospital readmission within 
6 months and the death of patients hospitalized for decom-
pensated HF. This result appears more relevant with respect 
to the improvement of some echocardiographic parameters 
(ejection fraction, diastolic volume).22 For the above reasons 
some authors propose BNP analysis for the clinical evaluation 
and therapy guidance of HF.23,24
Natriuretc peptides in CHF  
with preserved systolic function
LV systolic function is preserved in 40% to 50% of patients 
with CHF. The plasma levels of BNP correlate with echo-
cardiographic measurements of both ventricular systolic and 
diastolic dysfunction.25–30 Whereas the prognostic value of 
BNP in patients with impaired LV systolic function is well 
documented, there are a less data for patients with CHF 
and preserved systolic function. In a prospective study that 
included 161 patients, the probability of death within 12 
months after hospital admission was predicted by plasma 
levels of proBNP in patients with systolic dysfunction as 
well as in patients with preserved systolic function.31 Simi-
larly, proBNP values at discharge or changes in proBNP 
concentration during hospitalization were strong prognostic 
predictors of mortality, regardless of systolic function, in 
244 patients admitted for decompensated HF and followed 
for 6 months.32 Upcoming prospective trials will clarify the 
utility of NP in the prognosis and management of HF with 
preserved LVEF. It may be speculated that the association of 
high plasma NP levels and adverse outcomes could be sim-
ply a reflection of elevated filling pressures due to diastolic 
dysfunction. NP levels have been shown to correlate closely 
with LV end-diastolic wall stress, mitral E wave velocity 
and early diastolic wave tissue velocity ratio(E/e’) in the 
setting of HF and preserved systolic function.33–35 Arterial 
hypertension is accompanied by higher levels of BNP, a reli-
able indicator of LV pressure and/or volume overload.34 BNP 
levels are closely associated with LV hypertrophy and filling 
impairment and may be used to facilitate the diagnosis of 
LV diastolic dysfunction in hypertensives.35 Wall thickness 
during arterial hypertension is the major compensatory 
mechanism to pressure overload and it is often associated 
with myocardial fibrosis collagen deposition and reduction 
in LV relaxation and distensibility.36 Experimental studies 
demonstrated that the genetic expression of BNP in myocar-
dial tissue is one of the most important early indicators of 
LV pressure overload and it occurs before LV hypertrophy 
(LVH) development.37–39 However not all studies carried 
out on patients with high blood pressure showed the same 
results: while some researchers revealed that patients with 
LVH had high BNP levels, other researchers did not show 
a similar trend.40,41 Such a discordance is may be due to 
the different biases and populations enrolled in the stud-
ies. We believe that LVH alone is not a specific stimulus 
for BNP increase, increased NP levels could be firstly due 
to diastolic filling alterations independently from cardiac 
hypertrophy presence. In fact, the strongest correlations 
have been reported for BNP with LV diastolic wall stress 
which follows the stretch-mediated BNP secretion.33 BNP 
levels increase with the greater severity of overall dia-
stolic dysfunction, independently of LVEF, age, sex, body 
mass index, and renal function, and the highest levels are 
seen in subjects with restrictive filling patterns.42–44 BNP 
levels correlate with indexes of filling pressure, including 
transmitral early filling velocity (E) and its ratio to early 
diastolic annular velocity (E/Ea) – as well as with indexes 
of compliance and myocardial relaxation.43,44 In subjects 
with normal LVEF, elevated proBNP (600 pg/mL) or BNP 
(100 pg/mL) are the strongest independent predictors of 
severe diastolic dysfunction; low BNP levels (140 pg/mL) 
exhibit a very high, negative predictive value (90%) for 
diastolic dysfunction.43,44
Natriuretic peptide and right 
ventricular (RV) function
The right ventricle contributes to plasma levels of BNP or 
proBNP, with either normal or impaired LVEF. Levels of both 
peptides correlate with measures of RV size and function, 
increasing with greater dilatation and systolic dysfunction, 
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and with increasing RV pressure estimates.43,44 Few patients 
with pulmonary disease have a BNP levels 100 pg mL, or 
proBNP levels  350 pg/mL. In patients with pulmonary 
hypertension and RV dysfunction (eg, chronic obstruc-
tive pulmonary disease, pulmonary interstitial fibrosis or 
primary pulmonary hypertension) NP levels are often in 
a gray (unclear) zone or in a diagnostic zone for HF.45 The 
accuracy of NP to diagnose HF is unchanged in the presence 
of pre-existing pulmonary disease. NP levels may also be 
increased in the setting of acute RV strain as a result of a 
pulmonary embolism. NP levels should not replace the stan-
dard diagnostic process when this condition is foreseen as 
these levels are higher in more than 30% of patients and they 
are associated with a worse outcome particularly when they 
occur with an increase in RV pressure and volume.46,47
Although the left ventricle is considered the most 
important contractility chamber, several recent studies 
have shown the pivotal importance of RV function. RV 
systolic dysfunction is an independent prognostic factor 
in patients with moderate to severe HF, and it is strictly 
related to reduced effort tolerance and exercise training. 
Although initial studies showed that increased NP levels 
were associated with the severity of LV dysfunction some 
authors have recently shown that patients with both RV and 
LV dysfunction have increased levels.48–51 Again, studies 
conducted by magnetic resonance and tomography con-
firmed a negative correlation between right systolic func-
tion and BNP levels in patients affected to post-ischemic 
cardiomyopathy.52
Natriuretic peptides and gray zone:  
where echo is superior  
to the laboratory
Plasma BNP levels are a useful test in the diagnosis of 
HF with high sensivity and specificity and strong positive 
predictive values. However, in some circumstances, BNP 
measurements without clinical interpretation and knowledge 
are not best able to differentiate cardiogenic or other dyspnea. 
There are a few confounding factors that could potentially 
alter plasma BNP levels such as; gender, females have higher 
levels do males. Thus increased BNP levels have a greater 
predictive value for adverse events in women.53 NP also 
changes on the basis of the race: African-American and His-
panic subjects have higher levels than Caucasians in the same 
NYHA class.54 Renal insufficiency also leads to augmented 
BNP levels independent to HF presence. In the same way 
patients with anemia have higher BNP levels. Significantly 
Patients with acute
dyspnea
Diagnosis for heart failure
Physical examination, chest
x-ray, ECG, NP mesurement
BNP < 100 pg/mL
NT-proBNP < 300 pg/mL
BNP > 500 pg/mL
NT-proBNP > 1800 pg/mL
BNP 100–400 pg/mL
>300 NT-proBNP <  1800 pg/mL
HF very improbable 2% HF very probable 95%ECHO
(LV dimension and EF,
diastolic filling,
MR severity)
Figure 2 Decisional algorithm for HF diagnosis on the basis of NP measurement: in case of NP values in the gray zone it is necessary to confirm or exclude diagnosis by 
echocardiography
Abbreviations: eCG, electrocardiogram eF, ejection fraction; NP, natriuretic peptide; BNP, brain natriuretic peptide; NT-proBNP, N-terminal probrain natriuretic peptide; HF, 
heart failure; LV, left ventricle; MR, mitral regurgitation; eCHO, echocardiogram.
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increased levels have also been detected in patients with 
cardio-renal syndrome.55–57 Contrarily, obesity is associated 
with lower BNP levels even with concomitant hypertension 
or LV dysfunction.58 Finally supraventricular arrythmia such 
as atrial fibrillation is related to higher BNP levels, suggesting 
that a more elevated normal range should be considered in 
patients with atrial fibrillation for HF diagnosis.59 The lack 
of only one set of normal range values, due to the different 
idiopathic levels and commercially available analysis kits, 
make for further confusion for their clinical application. 
While some researchers state values of 100 pg/mL indicate 
HF, others suggest a value of 200 pg/mL. The ADHERE 
study, which included more than 48,000 patients, indicated 
the prognostic mortality values of 430 pg/mL.60 In all the 
cited conditions a careful clinical examination together with 
an echocardiographic examination evaluating systo-diastolic 
function should be complementary to BNP analysis for diag-
nostic strategy and treatment implementation.
A diagnostic “score” incorporating NP results with 
patient history and physical examination has been described.61 
Although they are more complex than the recommended 
1-step pathways for use of BNP testing, the algorithms for 
NT testing are clearer, providing much more information to 
the clinicians in clinical practice62 (Figure 2).
Conclusions
In CHF, measurement of BNP is among the strongest inde-
pendent predictors of all relevant clinical outcomes and is 
useful across the whole spectrum of HF disease severity. 
High BNP levels are related to ventricular dysfunction 
severity and more advanced HF stages. Confusing factors 
(including obesity and renal dysfunction) may complicate 
the clinical interpretation of circulating BNP levels in 
patients with chronic and stable HF and should be con-
sidered when patients are evaluated. Serial measurements 
of BNP in the chronic outpatient setting appear to convey 
additional prognostic value for relevant adverse outcomes, 
including death or destabilization of HF requiring hospi-
talization, and they are thus recommended in every clinical 
approach.
NP can facilitate diagnosis and guide HF therapy. Their 
increase is directly related to more advanced NYHA classes 
and to poor prognosis. A complete algorithm including clini-
cal, echocardiographic, and laboratory examinations will lead 
to a better stratification in the setting of HF.
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